Moderna, INC Form 4 insider transactions

Chief Legal Officer of Moderna, Shannon Thyme Klinger, reports the acquisition and disposal of common stock and restricted stock units.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on June 5, 2024, under a pre-arranged trading plan.

Chief Financial Officer of Moderna, James Mock, reports acquisition and disposal of company stock and performance stock units.

Stephen Hoge, President of Moderna, reports the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition and disposal of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock and restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the acquisition of 328 shares and the sale of 183 shares to cover tax obligations.

Stephen Hoge, President of Moderna, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of Moderna, James Mock, reports acquisition and disposal of Moderna shares related to restricted stock units.

Chief Legal Officer of Moderna, Shannon Thyme Klinger, reports acquisition and disposal of common stock and restricted stock units.

Noubar Afeyan, a director at Moderna, sold a portion of his holdings in the company's common stock on May 22, 2024, under a pre-arranged trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at $127.49 per share on May 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna's President, Stephen Hoge, reports the acquisition and disposition of company stock, including transactions to cover tax obligations related to vesting restricted stock units.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Stephen Berenson reported the vesting of restricted stock units and acquisition of stock options in Moderna, Inc.

Francois Nader, a director at Moderna, Inc., acquired stock options for 7,557 shares on May 6, 2024.

Director Paul Sagan acquired 7,557 stock options in Moderna, Inc. on May 6, 2024, according to a Form 4 filing.

Director Elizabeth E. Tallett acquired stock options in Moderna, Inc. on May 6, 2024.

Director Sandra Horning acquired stock options and restricted stock units in Moderna, Inc. on May 6, 2024.

Director Robert Langer of Moderna, Inc. was granted stock options for 7,557 shares on May 6, 2024, exercisable by May 6, 2025, or the next Annual Meeting of Stockholders.

Director Elizabeth Nabel reports the vesting of restricted stock units and acquisition of stock options.

Director Noubar Afeyan acquired stock options in Moderna, Inc. on May 6, 2024.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on May 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on April 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on April 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at $105.02 per share on April 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on April 10, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of common stock and restricted stock units.